SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation Y145H


Basic Characteristics of Mutations
Mutation Site Y145H
Mutation Site Sentence AY.4.2, a sublineage of the Delta variant, was considered a variant under investigation (VUI) and also gained the nickname ""Delta Plus,"" due to its extra mutations, Y145H and A222V.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region
Standardized Encoding Gene
Genotype/Subtype AY.4.2
Viral Reference -
Functional Impact and Mechanisms
Disease -
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location Bulgaria
Literature Information
PMID 35902787
Title Initial introduction and spread of the SARS-CoV-2 AY.4.2.1 Delta variant in Bulgaria, a genomic insight
Author Alexiev I,Giovanetti M,Cella E,Ivanov I,Stoikov I,Donchev D,Grigorova L,Gancheva A,Dimitrova R,Korsun N,Trifonova I,Philipova I,Dobrinov V,Grigorova I,Kantardjiev T,Christova I,Ciccozzi M
Journal Journal of medical virology
Journal Info 2022 Dec;94(12):6060-6064
Abstract The evolution of the emerging SARS-CoV-2 variants carrying mutations in the spike protein raises concerns about the possibility of accelerated transmission in the ever-evolving COVID-19 pandemic worldwide. AY.4.2, a sublineage of the Delta variant, was considered a variant under investigation (VUI) and also gained the nickname ""Delta Plus,"" due to its extra mutations, Y145H and A222V. In this study, using genomic epidemiology, we provide the first insights into the introduction of AY.4.2 in Bulgaria and the AY.4.2.1 sublineage that found larger dissemination only in Bulgaria and the United Kingdom.
Sequence Data EPI_ISL_4731435;EPI_ISL_5739135;EPI_ISL_5739272;EPI_ISL_5739283;EPI_ISL_5845625;EPI_ISL_5845717;EPI_ISL_5854826;EPI_ISL_5855123;EPI_ISL_5855126;EPI_ISL_5855137;EPI_ISL_5855145;EPI_ISL_5855169; EPI_ISL_5855177;EPI_ISL_5855180;EPI_ISL_5855190;EPI_ISL_6101740-EPI_ISL_6101764
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.